GlassScriptPhysician profile
Nikisha Onyenezi
NPI 1629614995
$685.80
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $391 · 2023: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $239.42 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.92 | 2021-2023 | Jardiance, Synjardy, Glyxambi |
| Astrazeneca Pharmaceuticals LP | $42.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.75 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $38.20 | 2021 | |
| Edwards Lifesciences Corporation | $34.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.62 | 2022 | |
| Novo Nordisk INC | $21.03 | 2023 | Ozempic, Rybelsus |
| Medicure Pharma INC. | $19.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.93 | 2022 | |
| Dexcom, INC. | $18.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.81 | 2021 | |
| Genentech USA, INC. | $17.70 | 2022 | |
| Eisai INC. | $17.08 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15.27 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.17 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikisha Onyenezi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.